- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05020132
Bowel Dysfunction After Rectal Cancer Treatment
September 26, 2023 updated by: Yolanda Ribas, Consorci Sanitari de Terrassa
Prospective Evaluation of Bowel Dysfunction After Rectal Cancer Treatment
Bowel dysfunction after rectal cancer treatment may significantly affect the quality of life.
Our study aimed to estimate the incidence and characterize the Low Anterior Resection Syndrome(LARS).
We performed a prospective evaluation of patients treated with anterior resection for rectal cancer at two hospitals.
Assessment was performed at baseline, after neoadjuvant treatment, and 1, 6 and 12 months after bowel transit reconstruction using the following scores: Bristol scale, LARS score, MSK-BFI, FIQL, EORTC-QLQ30 and a visual analogue scale.
Study Overview
Status
Completed
Conditions
Detailed Description
Low anterior resection syndrome (LARS) refers to wide-ranging symptoms including evacuatory dysfunction, fecal urgency and incontinence.
The assessment of bowel dysfunction after rectal cancer treatment has improved since the development of the LARS score.
This score has widely been used with a meta-analysis reporting a pooled prevalence of "major LARS" of 41%.
However, several studies have found a large proportion of patients with major LARS in the general population without rectal cancer raising questions about the specificity of this score.
Moreover, most studies on the prevalence of LARS do not include a baseline evaluation and, therefore, may not allow establishing whether the dysfunctions appeared after the treatment.
Consequently, we considered that a prospective study including a baseline evaluation and multiple validated questionnaires was required.
The present study aimed to estimate the incidence and characterize bowel dysfunction after rectal cancer treatment.
The results of this study will be useful to improve the preoperative information given to the patient and the shared decision-making process.
Study Type
Observational
Enrollment (Actual)
113
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Barcelona
-
Terrassa, Barcelona, Spain, 08227
- Consorci Sanitari de Terrassa
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
Patients with anterior resection for rectal adenocarcinoma with curative intention, with or without neoadjuvant chemoradiotherapy
Description
Inclusion Criteria:
Patients with anterior resection for rectal adenocarcinoma with curative intention, with or without neoadjuvant chemoradiotherapy, total or partial excision of the mesorectum, colorectal or coloanal anastomosis.
Exclusion Criteria:
- disseminated disease
- surgery with palliative intent
- refusal to participate in the study
- intellectual difficulty to answer the questionnaires
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the LARS score between baseline and 12 months
Time Frame: 12 months
|
Change in the LARS score (Low Anterior Resection Score) between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure).
The LARS score is a 5-item scoring system which classifies patients into three severity categories: no LARS (0-20 points), minor LARS (21-29 points), and major LARS (30-42 points).
A higher score represents worse bowel function.
This score also includes a question about the impact on quality of life.
|
12 months
|
Change in the MSK-BFI between baseline and 12 months (MSK-BFI)
Time Frame: 12 months
|
Change in the Memorial Sloan-Kettering Cancer Center Bowel Function Instrument (MSK-BFI) between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure).
The MSK-BFI includes 18 questions with five frequency options ranging from never through to always.
A total score and three subscales (frequency, diet, and urgency) can be calculated.
A higher score represents better bowel function.
|
12 months
|
Change in the Bristol stool chart between baseline and 12 months
Time Frame: 12 months
|
Change in the Bristol stool chart between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure).
The Bristol stool chart shows seven categories of stool.
The Bristol score was subclassified into three categories: Bristol 1-2 (hard stools), Bristol 3-4 (normal stools), and Bristol 5-7 (loose or liquid stools).
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the Visual Analogue Scale (VAS) between baseline and 12 months
Time Frame: 12 months
|
Change in the Visual Analogue Scale (VAS) between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure).
The VAS ranges from 0 (worst bowel function) to 10 (best)
|
12 months
|
Change in the EORTC QLQ-C30 between baseline and 12 months
Time Frame: 12 months
|
Change in the European Organization for Research and Treatment of Cancer Quality oF Life Questionnaire (EORTC QLQ-C30) between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure).
The EORTC QLQ-C30 is a self-administered questionnaire developed to assess the quality of life of patients with cancer.
The global QoL scale and 5 functional scales (physical, role, cognitive, emotional, and social functioning) can be calculated.
All scales range from 0 to 100.
A higher score for the global health status represents a higher quality of life, and a higher score for a functional scale represents a higher / healthy level of functioning.
|
12 months
|
Change in the Fecal Incontinence Quality of Life (FIQL) between baseline and 12 months
Time Frame: 12 months
|
Change in the Fecal Incontinence Quality of Life (FIQL) between baseline and 12 months after bowel transit reconstruction (primary surgery or ileostomy closure).
The FIQL score includes 29 items which form four scales: lifestyle, coping/behavior, depression/self-perception, and embarrassment.
Scores range from 0 to 4 and a higher value represents a better quality of life.
|
12 months
|
Correlation of the severity of LARS with the quality of life
Time Frame: 12 months
|
Correlation of the severity of LARS (LARS score and MSK-BFI) with the quality of life (EORTC QLQ-C30)
|
12 months
|
Multivariate analysis of risk factors for LARS
Time Frame: 12 months
|
Assessment of independent predictors of the LARS score at the 12-month visit in a multiple linear regression model.
Univariate linear regression analysis was initially performed to identify the demographic, clinical and surgical factors associated with the 12-month LARS score.
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2015
Primary Completion (Actual)
September 30, 2018
Study Completion (Actual)
September 1, 2020
Study Registration Dates
First Submitted
August 17, 2021
First Submitted That Met QC Criteria
August 18, 2021
First Posted (Actual)
August 25, 2021
Study Record Updates
Last Update Posted (Actual)
September 28, 2023
Last Update Submitted That Met QC Criteria
September 26, 2023
Last Verified
September 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- LARS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Low Anterior Resection Syndrome
-
Jewish General HospitalUniversity of Manitoba; McGill University Health Centre/Research Institute... and other collaboratorsRecruitingLow Anterior Resection Syndrome | Rectal Cancer | Surgery | Patient Activation | Low Anterior ResectionCanada, United States
-
HEM Pharma Inc.Premier Research Group plcNot yet recruitingLARS - Low Anterior Resection Syndrome
-
University Hospital, BordeauxTerminatedLow Anterior Resection Syndrome (LARS>20) | Refractory Medical Treatment After Rectal ResectionFrance
-
Innovacion en Cirugía VigoRecruitingLow Anterior Resection Syndrome | Rectal Disorders | Low Anterior ResectionSpain
-
National Cancer Institute, LithuaniaVilnius UniversityCompletedLow Anterior Resection SyndromeLithuania
-
Ismail GögenurAarhus University Hospital; Hvidovre University HospitalActive, not recruitingLow Anterior Resection SyndromeDenmark
-
Mirna Abraham-NordlingCompletedLow Anterior Resection SyndromeSweden
-
Coloplast A/SMedPass InternationalCompleted
-
Seoul National University HospitalRecruitingLARS - Low Anterior Resection SyndromeKorea, Republic of
-
Ankara UniversityAarhus University Hospital; Dokuz Eylul University; Lokman Hekim ÜniversitesiCompletedLARS - Low Anterior Resection Syndrome